Biotricity, Inc. (BTCY)
OTCMKTS · Delayed Price · Currency is USD
0.3850
-0.0030 (-0.77%)
Aug 1, 2025, 3:41 PM EDT
Biotricity Revenue
In the fiscal year ending March 31, 2025, Biotricity had annual revenue of $13.79M with 14.32% growth. Biotricity had revenue of $3.70M in the quarter ending March 31, 2025, with 16.50% growth.
Revenue
13.79M
Revenue Growth
+14.32%
P/S Ratio
0.75
Revenue / Employee
299.79K
Employees
46
Market Cap
10.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13.79M | 1.73M | 14.32% |
| Mar 31, 2024 | 12.06M | 2.42M | 25.15% |
| Mar 31, 2023 | 9.64M | 1.99M | 26.00% |
| Mar 31, 2022 | 7.65M | 4.27M | 126.02% |
| Mar 31, 2021 | 3.38M | 1.97M | 138.75% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Biotricity News
- 14 days ago - Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript - Seeking Alpha
- 16 days ago - Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach - GlobeNewsWire
- 17 days ago - Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th - GlobeNewsWire
- 4 months ago - Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed - GlobeNewsWire
- 5 months ago - Biotricity expands intellectual property portfolio with 14 new patents - Seeking Alpha
- 5 months ago - Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management - GlobeNewsWire
- 5 months ago - Biotricity GAAP EPS of -$0.05, revenue of $3.6M - Seeking Alpha
- 5 months ago - Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025 - GlobeNewsWire